UA89216C2 - Таблетка леветирацетама продолжительного высвобождения - Google Patents

Таблетка леветирацетама продолжительного высвобождения

Info

Publication number
UA89216C2
UA89216C2 UAA200709290A UAA200709290A UA89216C2 UA 89216 C2 UA89216 C2 UA 89216C2 UA A200709290 A UAA200709290 A UA A200709290A UA A200709290 A UAA200709290 A UA A200709290A UA 89216 C2 UA89216 C2 UA 89216C2
Authority
UA
Ukraine
Prior art keywords
levetiracetam
extended release
core
tablet
blood plasma
Prior art date
Application number
UAA200709290A
Other languages
English (en)
Ukrainian (uk)
Inventor
Раджеш Кширсагар
Маянк Джоши
Йогеш Раичандани
Original Assignee
Алембик Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35788072&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA89216(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Алембик Лимитед filed Critical Алембик Лимитед
Publication of UA89216C2 publication Critical patent/UA89216C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA200709290A 2005-01-27 2005-12-08 Таблетка леветирацетама продолжительного высвобождения UA89216C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN81MU2005 2005-01-27

Publications (1)

Publication Number Publication Date
UA89216C2 true UA89216C2 (ru) 2010-01-11

Family

ID=35788072

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200709290A UA89216C2 (ru) 2005-01-27 2005-12-08 Таблетка леветирацетама продолжительного высвобождения

Country Status (18)

Country Link
US (4) US7858122B2 (ru)
EP (1) EP1843761B1 (ru)
JP (1) JP5739080B2 (ru)
KR (1) KR20070095456A (ru)
CN (1) CN101111245A (ru)
AU (1) AU2005325930B2 (ru)
BR (1) BRPI0518506A2 (ru)
CA (1) CA2595988A1 (ru)
DE (1) DE05815688T1 (ru)
EA (1) EA014249B1 (ru)
ES (1) ES2294979T1 (ru)
IL (1) IL184822A0 (ru)
MX (1) MX2007009088A (ru)
NO (1) NO20074316L (ru)
NZ (1) NZ556630A (ru)
UA (1) UA89216C2 (ru)
WO (1) WO2006080029A1 (ru)
ZA (1) ZA200707250B (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909770B1 (en) * 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
WO2006102750A1 (en) * 2005-03-30 2006-10-05 Genpharm Inc. Combined-step process for pharmaceutical compositions
BRPI0606121A2 (pt) * 2005-07-26 2009-10-06 Ucb Pharma Sa composição farmacêutica, processo de manufaturar a mesma, e, uso de uma composição farmacêutica
MX2008013675A (es) 2006-04-26 2009-03-06 Supernus Pharmaceuticals Inc Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal.
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
US8444758B2 (en) * 2006-10-19 2013-05-21 Eastman Chemical Company Low voc additives for extending the wet edge and open time of aqueous coatings
US20080092776A1 (en) * 2006-10-19 2008-04-24 Rebecca Reid Stockl Low-VOC additives for extending wet edge and open times of coatings
FR2912056B1 (fr) * 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation
US20120003307A1 (en) * 2007-11-29 2012-01-05 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
US20100310652A1 (en) * 2007-12-21 2010-12-09 Alembic Limited Coated extended release pharmaceutical compositions of levetiracetam
US20090263481A1 (en) * 2008-04-17 2009-10-22 Atul Vishvanath Patil Levetiracetam formulations
BRPI0912161A2 (pt) * 2008-05-30 2015-10-06 Ucb Pharma Sa composição farmacêutica na forma de um tablete
CN101623250B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种左乙拉西坦药物组合物及其制备方法
WO2010025349A1 (en) * 2008-08-29 2010-03-04 Teva Pharmaceutical Industries Ltd. Modified release composition of levetiracetam and process for the preparation thereof
WO2010026467A2 (en) 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
CA2740610C (en) * 2008-10-16 2020-01-07 The Johns Hopkins University Synaptic vesicle protein 2a inhibitors for treating age-related cognitive impairment
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
CA2741038C (en) * 2008-11-18 2015-01-13 Ucb Pharma S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
CN101422442A (zh) * 2008-12-09 2009-05-06 沈阳药科大学 左乙拉西坦渗透泵控释片及其制备方法
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
CN101919811A (zh) * 2009-06-09 2010-12-22 北京博时安泰液体制剂科技有限公司 一种左乙拉西坦注射液及其制备方法
TR200905670A1 (tr) * 2009-07-22 2011-02-21 Sanovel �La� San.Ve T�C.A.�. Uzatılmış salım sağlayan levetirasetam farmasötik bileşimleri
CN101647789B (zh) * 2009-09-01 2011-08-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂
EP2298290A1 (en) 2009-09-16 2011-03-23 LEK Pharmaceuticals d.d. Controlled release composition comprising levetiracetam
CN102917697B (zh) 2010-03-24 2016-01-20 爵士制药有限公司 用于高剂量的水溶性和吸湿性药物的控释剂型
WO2011135430A1 (en) * 2010-04-29 2011-11-03 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
US9333175B2 (en) 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
KR20120055313A (ko) * 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
EP2646001A2 (en) * 2010-12-02 2013-10-09 UCB Pharma GmbH Formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
TR201011148A1 (tr) * 2010-12-30 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Levetirasetam farmasötik bileşimleri.
CA2877134A1 (en) * 2012-08-08 2014-02-13 PharmTak, Inc. Extended-release levetiracetam and method of preparation
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX2015011099A (es) * 2013-02-28 2016-04-06 Lupin Ltd Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.
RU2015140501A (ru) * 2013-02-28 2017-03-31 Люпин Лимитед Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
EP2968994B1 (en) * 2013-03-15 2018-08-15 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2878296A1 (en) 2013-11-29 2015-06-03 UCB Pharma GmbH Pharmaceutical composition comprising lacosamide and levetiracetam
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP3258921A1 (en) 2015-02-20 2017-12-27 UCB Biopharma SPRL Combination treatment
UA123308C2 (uk) * 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
CN105997914A (zh) * 2016-07-20 2016-10-12 南通雅本化学有限公司 一种左乙拉西坦组合药物及其制备方法
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CA3062158A1 (en) * 2017-05-02 2018-11-08 Lubrizol Advanced Materials, Inc. Improved extended release highly loaded drug compositions
JP6653931B2 (ja) * 2017-06-16 2020-02-26 丸石製薬株式会社 レベチラセタム含有ゲル経口医薬組成物
US11400052B2 (en) 2018-11-19 2022-08-02 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
JP2020094024A (ja) * 2018-12-14 2020-06-18 エルメッド株式会社 レベチラセタム含有フィルムコート錠及びその製造方法、並びにレベチラセタム含有フィルムコート錠の変色抑制方法
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
JP7300725B2 (ja) * 2020-02-27 2023-06-30 日新製薬株式会社 固形製剤及びその製造方法
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
IE58246B1 (en) * 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
JP3598049B2 (ja) * 1992-09-18 2004-12-08 山之内製薬株式会社 ハイドロゲル徐放性製剤
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6107492A (en) * 1998-05-08 2000-08-22 Ucb, S.A. Process for the preparation of levetiracetam
KR100660594B1 (ko) * 1999-03-31 2006-12-22 얀센 파마슈티카 엔.브이. 방출 조절형 제제중의 프리젤라틴화 전분
SE9903879D0 (sv) * 1999-10-28 1999-10-28 Ethical Pharmaceuticals Sweden Multipor food protection
EP1118321A1 (fr) * 2000-01-14 2001-07-25 Ucb, S.A. Compositions pharmaceutiques solides pour la libération contrôlée de substances actives
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040028729A1 (en) * 2002-04-29 2004-02-12 Shojaei Amir H. Pharmaceutical formulations with improved bioavailability
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
CN1802352A (zh) * 2003-02-03 2006-07-12 特瓦制药工业有限公司 制备左乙拉西坦的方法
EP1626721B1 (en) 2003-05-23 2016-12-07 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
IN2003MU00504A (ru) 2003-06-05 2005-05-13 Alembic Ltd
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
BRPI0417043A (pt) * 2003-12-01 2007-02-06 Lifecycle Pharma As composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição
US20050250838A1 (en) * 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
WO2006017159A1 (en) * 2004-07-09 2006-02-16 Drugtech Corporation Controlled phase composition technology as an improved process for protection of drugs
EP1909770B1 (en) 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
BRPI0606121A2 (pt) 2005-07-26 2009-10-06 Ucb Pharma Sa composição farmacêutica, processo de manufaturar a mesma, e, uso de uma composição farmacêutica
JP2009504590A (ja) 2005-08-08 2009-02-05 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつ剤型
US20080014264A1 (en) 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008062446A2 (en) 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect

Also Published As

Publication number Publication date
EP1843761B1 (en) 2018-01-31
JP2008528571A (ja) 2008-07-31
NZ556630A (en) 2010-12-24
CN101111245A (zh) 2008-01-23
EP1843761A1 (en) 2007-10-17
NO20074316L (no) 2007-08-23
EA200701575A1 (ru) 2008-02-28
US20070092569A1 (en) 2007-04-26
IL184822A0 (en) 2007-12-03
US7858122B2 (en) 2010-12-28
BRPI0518506A2 (pt) 2008-12-02
AU2005325930B2 (en) 2012-01-19
WO2006080029A1 (en) 2006-08-03
US20110064807A1 (en) 2011-03-17
JP5739080B2 (ja) 2015-06-24
US20110064808A1 (en) 2011-03-17
KR20070095456A (ko) 2007-09-28
DE05815688T1 (de) 2008-06-26
EA014249B1 (ru) 2010-10-29
ES2294979T1 (es) 2008-04-16
AU2005325930A1 (en) 2006-08-03
MX2007009088A (es) 2007-09-13
ZA200707250B (en) 2009-06-24
CA2595988A1 (en) 2006-08-03
US20060165796A1 (en) 2006-07-27
US7863316B2 (en) 2011-01-04

Similar Documents

Publication Publication Date Title
UA89216C2 (ru) Таблетка леветирацетама продолжительного высвобождения
WO2008062446A3 (en) An extended release composition of levetiracetam, which exhibits no adverse food effect
JP5788331B2 (ja) 浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤
HU229312B1 (hu) Szabályozott hatóanyag-leadású gyógyszer-dózisformák legalább egy idõzített gyors szakaszt magába foglaló szabályozott hatóanyag-leadásra
RU2011110765A (ru) Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения
JP2008520736A5 (ru)
WO2006123357A3 (en) Oral controlled release composition containing levetiracetam
AU2018278332A1 (en) Methods and compositions for treating excessive sleepiness
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
JP6993502B2 (ja) Ｓｇｌｔ－２阻害剤とアンジオテンシン受容体拮抗薬を含む医薬組成物
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
CA2488868A1 (en) Controlled release formulation of lamotrigine
WO2002028376A3 (en) Chrono delivery formulations and method of use thereof
JP2019529570A5 (ru)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
WO2007086079A3 (en) Sustained release dosage form of phenothiazine derivatives containing channelizer
MX2011007779A (es) Formulaciones galenicas de compuestos organicos.
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
EP2994112A1 (en) Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
CN109453169A (zh) 草乌甲素的用途
PT1387836E (pt) Derivados de ftalazina com actividade de inibição de angiogénese
CN101389330A (zh) 采用氨基异吲哚啉化合物治疗皮肤狼疮的方法
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
CN114432446B (zh) 抗组胺药在制备抗肿瘤药物中的应用
JP2008527034A5 (ru)